The common mycobacterial antigens and their importance in the treatment of disease

Current Pharmaceutical Design

Volumn 15, Issue 11, 2009, Pages 1248-1260

  Stanford, John ^a   Stanford, Cynthia ^a   Stansby, Gerard ^b   Bottasso, Oscar ^c   Bahr, Georges ^d   Grange, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^d UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

Actinomycetales; Common antigens; Heat shock stress proteins; Immunotherapy; Mycobacterium vaccae

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIUM ANTIBODY; BCG VACCINE; HEAT SHOCK PROTEIN; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM VACCINE; PLACEBO;

ADJUVANT THERAPY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOIMMUNITY; BACTERIAL STRAIN; BURULI ULCER; CELLULAR IMMUNITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS REACTION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; EUKARYOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LEISHMANIASIS; LEPROMATOUS LEPROSY; LUPUS VULGARIS; LYMPHOCYTE PROLIFERATION; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MYCOBACTERIOSIS; MYCOBACTERIUM VACCAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SKIN TEST; SYSTEMIC DISEASE; TH1 CELL; TH2 CELL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TRYPANOSOMIASIS; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; AUTOIMMUNE DISEASES; HEAT-SHOCK PROTEINS; HUMANS; HYPERSENSITIVITY; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; SKIN TESTS;

EID: 65649109749     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846838     Document Type: Review

References (129)

1. Stanford JL, Grange JM. The meaning and structure of species as applied to mycobacteria. Tubercle 1974; 55: 143-52.
2. Stanford JL, Revill WDL, Gunthorpe WJ, Grange JM. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Camb) 1975; 74: 7-16.
3. Lockwood DNJ, McManus IC, Stanford JL, Thomas A, Abeyagunawardana DVP. Three types of human response to mycobacterial antigen: population studies in India and Sri Lanka. Eur J Respir Dis 1987; 71: 348-55.
4. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 1959; 43: 273-90.
5. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 1995; 154: 3359-72.
6. Lund PA, Large AT, Kapatai G. The chaperonins: perspectives from the Archaea. Biochem Soc Trans 2003; 31: 681-5.
7. Macario AJ, Malz M, Conway de Macario E. Evolution of assisted protein folding: the distribution of the main chaperoning systems within the phylogenetic domain Archaea. Front Biosci 2004; 9: 1318-32.
8. Ouchterlony O. In vitro method for testing the toxin-producing capacity of diphtheria bacteria. Acta Pathol Microbiol Scand 1949; 26: 516-24.
9. Burdon RH. Heat shock and the heat shock proteins. Biochem J 1986; 240: 313-24.
10. Dudani AK, Gupta RS. Immunological characterization of a human homolog of the 65-kilodalton mycobacterial antigen. Infect Immun 1989; 57: 2786-93.
11. Garsia RJ, Hellqvist L, Booth RJ, Radford AJ, Britton WJ, Astbury L, et al. Homology of the 70-kilodalton antigens from Mycobacterium leprae and Mycobacterium bovis with the Mycobacterium tuberculosis 71-kilodalton antigen and with the conserved heat shock protein 70 of eucaryotes. Infect Immun 1989; 57: 204-12.
12. Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones 2006; 11: 116-28.
13. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
14. Stanford JL, Rook GAW. Environmental mycobacteria and immunisation with BCG. In: Easmon CSF, Jeljaszewicz J, Eds. Medical Mictobiology. London: Academic Press 1983; 2: 43-69.
15. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol 1999; 163: 2249-55.
16. Fontanella GH, Pascutti MF, Daurelio L, Perez AR, Nocito AL, Wojdyla D, et al. Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales. Vaccine 2007; 25: 3492-500.
17. Sghaier H, Le Huyen Ai T, Horiike T, Shinozawa T. Molecular chaperones: proposal of a systematic computer-oriented nomenclature and construction of a centralized database. In Silico Biol 2004; 4: 311-22.
18. Harrison GS, Drabkin HA, Kao FT, Hartz J, Hart IM, Chu EH, et al. Chromosomal location of human genes encoding major heat-shock protein HSP70. Somat Cell Mol Genet 1987; 13: 119-30.
19. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu Rev Physiol 1999; 61: 243-82.
20. Henderson B, Allan E, Coates ARM. Stress wars: the direct role of host and bacterial molecular chaperones in bacterial infection. Infect Immun 2006; 74: 3693-706.
21. Rashmi R, Kumar S, Karunagaran D. Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 2004; 25: 179-187.
22. Creagh EM, Sheehan D, Cotter TG. Heat shock proteins - modulators of apoptosis in tumour cells. Leukaemia 2000; 14: 1161-73.
23. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications Cell Stress Chaperones 2005; 10: 86-103.
24. Basu S, Srivastava PK. Heat shock proteins: the fountainhead of innate and adaptive immune responses. Cell Stress Chaperones 2000; 5: 443-51.
25. Karopoulos C, Rowley MJ, Handley CJ, Strugnell RA. Antibody reactivity to mycobacterial 65 kDa heat shock protein: relevance to autoimmunity. J Autoimmun 1995; 8: 235-48.
26. Jones DB, Hunter NR, Duff GW. Heat-shock protein 65 as a beta cell antigen of insulin-dependent diabetes. Lancet 1990; 336: 583-5.
27. Gruber R, Lederer S, Bechtel U, Lob S, Riethmüller G, Feucht HE. Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int Arch Allergy Immunol 1996; 110: 95-8.
28. Horváth L, Czirják L, Fekete B, Jakab L, Prohászka Z, Cervenak L, et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett 2001; 75: 103-9.
29. Young DB, Ivanyi J, Cox JH, Lamb JR. The 65kDa antigen of mycobacteria - a common bacterial protein? Immunol Today 1987; 8: 215-19.
30. Panchapakesan J, Daglis M, Gatenby P. Antibodies to 65 kDa and 70 kDa heat shock proteins in rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol 1992; 70: 295-300.
31. Bahr GM, Rook GAW, Shahin A, Stanford JL, Sattar MI, Behbehani K. HLA-DR associated isotype specific regulation of antibody levels to mycobacteria in rheumatoid arthritis. Clin Exp Immunol 1987; 72: 26-31.
32. Tsoulfa G, Rook GA, Bahr GM, Sattar MA, Behbehani K, Young DB, et al. Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol 1989; 30: 519-27.
33. Yokota S, Hirata D, Minota S, Higashiyama T, Kurimoto M, Yanagi H, et al. Autoantibodies against chaperonin CCT in human sera with rheumatic autoimmune diseases: comparison with antibodies against other Hsp60 family proteins. Cell Stress Chaperones 2000; 5: 337-46.
34. Rambukkana A, Das PK, Witkamp L, Yong S, Meinardi MM, Bos JD. Antibodies to mycobacterial 65-kDa heat shock protein and other immunodominant antigens in patients with psoriasis. J Invest Dermatol 1993; 100: 87-92.
35. Izaki S, Goto Y, Kitamura K, Nomaguchi H. Antibody to 65-kD stress protein (HSP65) of Mycobacterium leprae in various inflammatory skin diseases. A preliminary report. Nippon Rai Gakkai Zasshi 1994; 63: 3-11.
36. Prohászka Z, Daha MR, Süsal C, Daniel V, Szlávik J, Bánhegyi D, et al. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin Immunol 1999; 90: 247-55.
37. Yang M, Wu T, Cheng L, Wang F, Wei Q, Tanguay RM. Plasma antibodies against heat shock protein 70 correlate with the incidence and severity of asthma in a Chinese population. Respir Res 2005; 6: 18.
38. Prohászka Z, Duba J, Lakos G, Kiss E, Varga L, Jánoskuti L, et al. Antibodies against human heat-shock protein (hsp) 60 and mycobacterial hsp65 differ in their antigen specificity and complement-activating ability. Int Immunol 1999; 11: 1363-70.
39. Kalabay L, Fekete B, Czirják L, Horváth L, Daha MR, Veres A, et al. Helicobacter pylori infection in connective tissue disorders is associated with high levels of antibodies to mycobacterial hsp65 but not to human hsp60. Helicobacter 2002; 7: 250-6.
40. Huszti Z, Bene L, Kovács A, Fekete B, Füst G, Romics L, et al. Low levels of antibodies against E. coli and mycobacterial 65kDa heat shock proteins in patients with inflammatory bowel disease. Inflamm Res 2004; 53: 551-5.
41. Prohászka Z, Duba J, Horváth L, Császár A, Karádi I, Szebeni A, et al. Comparative study on antibodies to human and bacterial 60 kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur J Clin Invest 2001; 31: 285-92.
42. Rota S, Rota S. Mycobacterium tuberculosis complex in atherosclerosis. Acta Med Okayama 2005; 59: 247-51.
43. Rota S, Tuncer S, Rota S, Kanat O. Mycobacterium tuberculosis complex DNA does not exist in atheromatous plaques. N Microbiol 2005; 28: 165-9.
44. Alibasoglu M, Dunne HW, Guss SB. Naturally occurring arteriosclerosis in cattle infected with Johne's disease. Am J Vet Res 1962; 23: 49-57.
45. Xu Q, Kiechl S, Mayr M, Metzler B, Egger G, Oberhollenzer F, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999; 100: 1169-74.
46. Mukherjee M, De Benedictis C, Jewitt D, Kakkar VV. Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Thromb Haemost 1996; 75: 258-60.
47. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76.
48. Tsan MF, Gao B. Heat shock protein and innate immunity. Cell Mol Immunol 2004; 1: 274-9.
49. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
50. Cohen IR, Young DB. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991; 12: 105-10.
51. Poletaev A, Osipenko L. General network of natural autoantibodies as immunological homunculus (Immunculus). Autoimmun Rev 2003; 2: 264-71.
52. van Eden W. Immunoregulation of autoimmune diseases. Hum Immunol 2006; 67: 446-53.
53. van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: How immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Ann N Y Acad Sci 2007; 1113: 217-37.
54. Munk ME, Schoel B, Modrow S, Karr RW, Young RA, Kaufmann SH. T lymphocytes from healthy individuals with specificity to self-epitopes shared by the mycobacterial and human 65-kilodalton heat shock protein. J Immunol 1989; 143: 2844-9.
55. Prohászka Z. Chaperones as part of immune networks. Adv Exp Med Biol 2007; 594: 159-66.
56. Nardai G, Végh EM, Prohászka Z, Csermely P. Chaperone-related immune dysfunction: an emergent property of distorted chaperone networks. Trends Immunol 2006; 27: 74-9.
57. Macario AJL, Conway de Macario E. Sick chaperones, cellular stress and disease. N Engl J Med 2005; 353: 1489-1501.
58. Stanford JL, Stanford CA, Grange JM. Environmental echoes. Sci Prog 2001; 84: 105-24.
59. Rook GA, Stanford JL. Give us this day our daily germs. Immunol Today 1998; 19: 113-6.
60. Sakaguch S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 2005; 6: 345-52.
61. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004; 10: 801-5.
62. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6: 353-60.
63. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7: 875-88.
64. Bahr GM, Sattar MI, Stanford JL, Shaaban MA, Al Shimali B, Siddiqui Z, et al. HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis. Ann Rheum Dis 1988; 48: 63-8.
65. Rondelli FM, Mahuad CV, Gentiletti A, Goñi M, Pons-Estel B, Bottasso O, et al. Altered production of IFN-gamma? And other inflammation-related cytokines by mycobacteria- stimulated peripheral blood mononuclear cells from rheumatoid arthritis patients. Cell Mol Biol (Noisy-le-Grand) 2006; 52: 59-64.
66. Dlugovitzky D, Bottasso O, Dominino JC, Valentini E, Hartopp R, Singh M, et al. Clinical and serological studies of tuberculosis patients in Argentina receiving immunotherapy with Mycobacterium vaccae (SRL 172). Respir Med 1999; 93: 557-62.
67. Draper P, Rees RJW. Proposed system for preparing purified suspensions of M. leprae from tissues of infected armadillos. Lepr Rev 1976; 47: 197-203.
68. McManus IC, Lockwood DNJ, Stanford JL, Shaaban MA, Abdul Ati M, Bahr GM. Recognition of a category of responders to group ii, slow-grower associated antigens amongst Kuwaiti senior school children. Tubercle 1988; 69; 275-81.
69. Potts RC, Beck JS, Gibbs JH, Grange JM, Kardjito T, Stanford JL. Measurements of blood flow and histometry of the cellular infiltrate in tuberculin skin test responses of the typical Koch-type and the non-turgid (Listeria-type) in pulmonary tuberculosis patients and apparently healthy controls. Int J Exp Pathol 1992; 73: 565-72.
70. Hernandez-Pando R, Rook GA. The role of TNF-alpha in T-cellmediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994; 82: 591-5.
71. Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco H, Rook G. Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-α and in the regulation of fibrosis. Eur J Immunol 2004; 34: 174-83.
72. Rook GA, Hernandez-Pando R, Dheda K, Teng SG. IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 2004; 25: 483-8.
73. Beck JS, Gibbs JH, Potts RC, Kardjito T, Grange JM, Jawad ES, et al. Histometric studies on biopsies of tuberculin skin tests showing evidence of ischaemia and necrosis. J Pathol 1989; 159: 317-22.
74. Stanford JL, Bahr GM, Rook GAW, Shaaban MA, Chugh TD, Gabriel M, et al. Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle 1990; 71: 87-93.
75. Bahr GM, Shaaban MA, Gabriel M, Al Shimali B, Siddiqui Z, Chugh TD, et al. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle 1990; 71: 259-66.
76. Kardjito T, Beck JS, Grange JM, Stanford JL. A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Eur J Respir Dis 1986; 69: 142-5.
77. Onyebujoh P, Abdulmumini T, Robinson S, Rook GAW, Stanford JL. Immunotherapy for tuberculosis in African conditions. Respir Med 1995; 89: 199-207.
78. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae. 1. In the treatment of newly diagnosed pulmonary tuberculosis in Romania. Respir Med 1997; 91: 13-9.
79. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae. 2 In the treatment of chronic or relapsed tuberculosis in Romania. Respir Med 1997; 91: 21-9.
80. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Hom DL, et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J Infect Dis 2000; 181: 1304-12.
81. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354: 116-9.
82. Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial. Lancet 2002; 360: 1050-5.
83. Dlugovitzky D, Fiorenza G, Farroni M, Bogue C, Stanford C, Stanford J. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis. Respir Med 2006; 100: 1079-87.
84. De Bruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis Cochrane database. Syst Rev 2001; CD001166.
85. Etemadi A, Farid R, Stanford JL. Immunotherapy for drug-resistant tuberculosis (letter). Lancet 1992; 340: 360-1.
86. Stanford JL, Stanford CA, Grange JM, Lan NN, Etemadi A. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? Respir Med 2001; 95: 444-7.
87. Stanford JL, Terencio de las Aguas J, Torres P, Gervasioni BO, Ravioli R.Studies on the effects of a potential immunotherapeutic agent in leprosy patients. Health Cooperation Papers. Proceedings of the Fourth European Leprosy Symposium 1987; 7: 201-206.
88. Stanford JL, Torres P, Terencio de las Aguas J. Immunoterapia en pacientes de lepra lepromatosa de Fontilles. Rev Leprol Fontilles 1985; 15: 309-312.
89. Ramu G, Grange J, Stanford J. Evaluation of adjunct immunotherapy with killed Mycobacterium vaccae in the treatment of multibacillary leprosy and erythema nodosum leprosum. In Casal M, ed. Clinical Mycobacteriology. Barcelona: Prous Science 1998; 393-402.
90. Zaheer SA, Misra RS, Sharma AK Beena KR, Kar HK, Mukherjee A, et al. Immunotherapy with Mycobacterium w vaccine decreases the incidence and severity of type 2 (ENL) reactions. Lepr Rev 1993; 64: 7-14.
91. Abbot NC, Beck JS, Feval F, Weiss F, Mobayen MH, Ghazi-Saidi K, et al. Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo- controlled trial. Eur J Vasc Endovasc Surg 2002; 24: 202-8.
92. Khoo SH, Wilkins EG, Fraser IS, Hamour AA, Stanford JL. Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts. Thorax 1996; 51: 932-5.
93. Amiel C, Kusnierz JP, Rook G, Stanford J, Singh M, Capron A, et al. Cytokine analysis at the single cell level and lymphoproliferative responses to mycobacterial antigens in HIV-1 patients with successful virologic response to potent antiretrovirals. J Clin Immunol 2000; 20: 458-65.
94. von Reyn CF, Marsh BJ, Waddell R, Lein AD, Tvaroha S, Morin P, et al. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus positive subjects in the United States after a five dose schedule of Mycobacterium vaccae vaccine. Clin Infect Dis 1998; 27: 1517-20.
95. Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000; 30(Suppl 3): S309-15.
96. Vuola JM, Ristola MA, Cole B, Jarviluoma A, Tvaroha S, Ronkko T, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomised, controlled trial. AIDS 2003; 17: 2351-5.
97. Stanford JL, Onyebujoh PC, Rook GAW, Grange JM, Pozniak A. Old plague, new plague and a treatment for both? (letter). AIDS 1993; 7: 1275-7.
98. Bottasso OA, Ingledew N, Keni M, Morini J, Pividori JF, Rook GA, et al. Cellular immune response to common mycobacterial antigens in subjects seropositive for Trypanosoma cruzi. Lancet 1994; 344: 1540-1.
99. Roth A, Gustafson P, Nhaga A, Djana O, Garly ML, Jensen H, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34: 540-7.
100. Valian HK, Kenedy LKA, Rostami MN, Mohammadi AM, Khamesipour A. Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis. Parasitol Res 2008; 103: 21-8.
101. Bibakis I, Zekveld C, Dimitroulis I, Pedioti A, Gerakianaki T, Fanourgiaki S, et al. Childhood atopy and allergic disease and skintest responses to environmental mycobacteria in rural Crete: a cross-sectional survey. Clin Exp Allergy 2005; 35: 624-9.
102. Camporota L, Corkhill A, Long H, Lordan J, Stanciu L, Tuckwell N, et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 2003; 21: 287-93.
103. Hopkin JM, Ferry B, Coull P, Antrobus P, Enemoto T, Yamashita T, et al. Mycobacterial immunisation in grass pollen asthma and rhinitis. Thorax 1998; 53: 63.
104. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172)is associated with improvement in atopic dermatitis in children with moderate-tosevere disease. J Allergy Clin Immunol 2001; 107: 531-4.
105. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-99.
106. George J, Shoenfeld Y, Gilburd B, Afek A, Shaish A, Harats D. Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res 2000; 86: 1203-10.
107. Stansby G, Chan YC, Berwanger CS, Shurey S, Rook GA, Stanford JL. Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 2002; 23: 23-8.
108. Hansson GK, Robertson AL, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.
109. Bay ML, Lehrer A, Bressanelli A, Morini J, Bottasso O, Stanford J. Psoriasis patients have T-cells with reduced responsiveness to common mycobacterial antigens. FEMS Immunol Med Microbiol 1998; 21: 65-70.
110. Lehrer A, Bressanelli A, Wachsmann V, Bottasso O, Bay ML, Singh M, et al. Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 1998; 21: 71-7.
111. van Eden W, de Vries RR, Stanford JL, Rook GA. HLA-Dr3 associated genetic control of response to multiple skin tests with new tuberculin's. Clin Exp Immunol 1983; 52: 287-92.
112. Ottenhoff TH, Torres P, Terencio de-las-Aguas J, Fernandez R, van Eden W, de Vries RR, et al. Evidence for an HLA-DR4-associated immune-response gene for Mycobacterium tuberculosis. A clue to the pathogenesis of rheumatoid arthritis. Lancet 1986; 2: 310-13.
113. Thompson SJ, Butcher PD, Patel VKR, Rook GAW, Stanford JL, Van der Zee R, et al. Modulation of pristane-induced arthritis by mycobacterial antigens. Autoimmunity 1991; 11: 35-43.
114. Sinclair H, Erkeller-Yuksel F, Sharif M, Rook GAW, Lydyard PM, Isenberg DA, et al. Preliminary report of an open study of Mycobacterium vaccae immunisation in rheumatoid arthritis. Br Soc Rheumatol 1991; Summer meeting abstract.
115. Baban B. The evaluation of a heat-killed suspension of Mycobacterium vaccae as an immodulating agent in the treatment of cancer. PhD Thesis: University of London 1998.
116. Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999; 10: 817-24.
117. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 82: 568-73.
118. Stanford JL, Stanford CA, O'Brien M, Grange JM. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008; 44: 224-7.
119. Patel PM, Sim S, O'Donnell DO, Protheroe A, Beirne D, Stanley A, et al. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 2008; 44: 216-23.
120. Grange JM, Bottasso O, Stanford CA, Stanford JL. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008; 26: 4084-90.
121. Gilham C, Peto J, Simpson J, Roman E, Eden TO, Greaves MF, et al. Day care in infancy and risk of childhood acute lymphoblastic leukaemia: findings from UK case-control study. Br Med J 2005; 330: 1294.
122. Pearl R. Cancer and tuberculosis. Am J Hyg 1929; 9: 97-162.
123. Garly ML, Martins CL, Balé C, Baldé MA, Hedegaard KL, Gustafson P, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine 2003; 21: 2782-90.
124. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 1339-45.
125. Stanford JL, Stanford CA, Baban B, Grange JM. Therapeutic vaccination for cancer: the potential value of mycobacterial products. Int J Pharmaceut Med 1999; 12: 191-5.
126. Grange JM, Stanford JL. BCG vaccination and cancer. Tubercle 1990; 71: 61-4.
127. Krone B, Kölmel KF, Grange JM, Mastrangelo G, Henz BM, Botev IN, et al. Impact of vaccinations and infectious diseases on melanoma risk - evaluation of an EORTC case-control study. Eur J Cancer 2003; 39: 2372-8.
128. Kölmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer 2005, 41: 118-25.
129. Wu T, Tanguay RM. Antibodies against heat shock proteins in environmental stresses and diseases: friend or foe? Cell Stress Chaperones 2006; 11: 1-12.